Serum CA19-9 Decline Compared to Radiographic Response as a Surrogate for Clinical Outcomes in Patients With Metastatic Pancreatic Cancer Receiving Chemotherapy
The DOI matches its Crossref record.
Abstract
OBJECTIVE: Serum carbohydrate antigen 19-9 (CA19-9) has never been compared to radiographic objective response as a surrogate for clinical outcomes in patients receiving chemotherapy for metastatic pancreatic cancer. METHODS: We compared CA19-9 decline to objective response as surrogate end points for both time to progression (TTP) and overall survival (OS) in patients with metastatic pancreatic cancer receiving fixed-dose rate gemcitabine. RESULTS: A total of 75 patients from 2 studies were eligible for analysis. Significant correlations were observed between maximum CA19-9 decline and both TTP (P < 0.0001) and OS (P < 0.0001). Median OS was 12.2 months for patients with more than a 75% decline in CA19-9, 7.5 months for those with 0% to 75% decline, and 3.5 months for those with no decline. Correlations between best radiographic response and both TTP (P < 0.0001) and OS (P=0.0013) were also observed. Median OS was 12.8 months for patients with partial or complete response, 8.0 months for those with stable disease, and 4.6 months for those with progressive disease. CONCLUSIONS: CA19-9 decline compares favorably with objective response as a strong predictor of TTP and OS. CA19-9 could represent amore cost-effective tool for the evaluation of new therapies and guidance of clinical management in patients with metastatic pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mizrahi, J. D., Surana, R., Valle, J. W., & Shroff, R. T. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30974-0 · Cited by 2,559
Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter
Luo, G., Jin, K., Deng, S., Cheng, H., Fan, Z., Gong, Y., Qian, Y., Huang, Q., Ni, Q., Liu, C., et al. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188409 · Cited by 446
The prognostic and predictive value of serum CA19.9 in pancreatic cancer
Humphris, J. L., Chang, D. K., Johns, A. L., Scarlett, C. J., Pajic, M., Jones, M. D., Colvin, E. K., Nagrial, A., Chin, V. T., Chantrill, L. A., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr561 · Cited by 312
Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer
Winter, J. M., Yeo, C. J., & Brody, J. R. (2013) · Journal of Surgical Oncology · doi:10.1002/jso.23192 · Cited by 234
Tsai, S., George, B., Wittmann, D., Ritch, P. S., Krepline, A. N., Aldakkak, M., Barnes, C. A., Christians, K. K., Dua, K., Griffin, M., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000003049 · Cited by 222
“001 Age in years, median (IQR) 65 (12) 65 (13) 66 (11) 63 (10) 66 (12) 0.”
Jenkinson, C., Elliott, V. L., Evans, A., Oldfield, L., Jenkins, R. E., O'Brien, D. P., Apostolidou, S., Gentry-Maharaj, A., Fourkala, E.-O., Jacobs, I. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0879 · Cited by 87
“CA19-9, the only biomarker in routine use for the management of pancreatic cancer (2, 3) has a number of limitations including lack of expression in approximately 5% of the population, and elevation in related diseases including chronic pancreatitis and obstructive jaundice (2, 4).”
BackgroundTonack, S., Jenkinson, C., Cox, T., Elliott, V, Jenkins, R. E., Kitteringham, N. R., Greenhalf, W., Shaw, V, Michalski, C. W., Friess, H., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.150 · Cited by 70
Biomarkers for early diagnosis of pancreatic cancer
Jenkinson, C., Earl, J., Ghaneh, P., Halloran, C., Carrato, A., Greenhalf, W., Neoptolemos, J., & Costello, E. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.965145 · Cited by 42
“Currently, the only biomarker used in the routine management of pancreatic cancer is CA19-9, an epitope of sialylated Lewis blood group antigen [9,10].”
Background
Metadata
- Authors
- Wong, D., Ko, A. H., Hwang, J., Venook, A. P., Bergsland, E. K., & Tempero, M. A.
- Venue
- Pancreas
- Published
- 2008-10
- Volume
- 37
- Issue
- 3
- Pages
- 269-274
- ISSN
- 0885-3177 (ISSN-L)
- OpenAlex
- W2034983280
- Cited by
- 89
- References
- 0
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.